Adjuvanted influenza vaccine

BioDrugs

Volumn 14, Issue 1, 2000, Pages 61-69

  Dooley, Mukta ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

ADULT; AGED; CLINICAL TRIAL; DRUG INDUCED DISEASE; HUMAN; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; META ANALYSIS; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME; VACCINATION; VIRUS INFECTION;

EID: 0033827068     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200014010-00006     Document Type: Review

References (15)

1. Influenza vaccines: A reappraisal of their use
2. Improvement of inactivated influenza virus vaccines
3. Adjuvants for human vaccines - Current status, problems and future prospects
4. Dendritic cells internalize vaccine adjuvant after intramuscular injection
5. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons
6. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly
7. Influenza vaccines: Antibody responses to split virus and MF59-adjuvanted subunit virus in an adult population
8. Anti-influenza vaccination in elderly subjects: Experience with adjuvanted vaccines
9. Safety of inactivated influenza virus vaccines (ISIVVs) combined with MF59 adjuvanted emulsion